Aller au contenu principal
Accès ouvert déclaré 2025 article

The effect of excipients on the oral absorption of pimobendan in healthy dogs

0Citations signalées, ce qui n’est pas une note de qualité
3Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : us. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Compounded pimobendan is prescribed without knowledge of the effect of excipients. The objective of this study was to test the effect of certain excipients on oral absorption in dogs by describing the single-dose pharmacokinetics of pimobendan and its active metabolite (o-desmethyl-pimobendan [ODMP]) following oral administration of two experimental pimobendan formulations, and to compare these pharmacokinetic estimates to those of an FDA-approved product (Vetmedin®). Seven healthy adult purpose-bred dogs Dogs were administered 2.5 mg of pimobendan as a single oral dose of Vetmedin®, or of an experimental capsule with or without citrate as an excipient, in a randomized, prospective cross-over study with a two-week washout period between treatments. Blood samples were obtained at pre-determined timepoints before and for 24 hours post-dose for quantification of pimobendan and ODMP using ultra-high-pressure liquid chromatography with mass spectrometry. Compartmental analysis was used to obtain pharmacokinetic parameters. Data are presented as geometric mean (CV%). Peak plasma pimobendan concentrations (C MAX ) were 8.82 ng/mL (53%), 5.85 ng/mL(76%), and 8.11 ng/mL (70%), and areas under the concentration-time curve (AUC) were 19.0 hr*ng/mL (55%), 13.6 hr*ng/mL (68%) and 19.7 hr*ng/mL (40%) for Vetmedin®, citrate-containing capsules and citrate-free capsules, respectively. Experimental formulations had high relative absorption (AUC (test drug) /AUC (Vetmedin®) , 72% [61%] and 103% [71%] for citrate-containing and citrate free-capsules, respectively). There was moderate-to-high inter-individual pharmacokinetic variability for all formulations. No differences in C MAX or AUC were found among treatments. Small sample size This study did not identify differences in relative bioavailability among the tested formulations; however, bioequivalence should not be assumed. Substantial inter-individual pharmacokinetic variability was noted.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
The effect of excipients on the oral absorption of pimobendan in healthy dogs
Date Crossref
01/02/2026
Éditeur
Elsevier BV
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Cardiovascular Conditions and TreatmentsVeterinary Oncology ResearchVeterinary Pharmacology and Anesthesia

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.